Figure 3
From: Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole
6OTD preferentially targets glioma stem cells rather than non-stem glioma cells. (A) Representative photos of glioma stem cells (GSCs) and non-stem glioma cells (NSGCs). GSCs were differentiated into NSGCs by serum stimulation for 7 days12, 21. (B) Effects of 6OTD and TMS on the growth of two patient-derived GSCs and NSGCs. Cells were treated with indicated concentrations of the compounds for 6 days. Graphs indicate the mean ± SD of triplicate assays. (C) Cell-cycle analysis of GSCs and NSGCs treated with 6OTD (0 or 100 nM, 5 days) by flow cytometry with propidium iodide (PI) staining, with the number of cell (x-axis) and DNA content (y-axis). Indicated histograms are the representative results of duplicate experiments. (D) Quantitation of the cell-cycle distribution of control and 6OTD-treated GSCs and NSGCs in (C). (E) Detection of PARP cleavage in GSCs and NSGCs. Cells were lysed 5 days after DMSO, 6OTD (100 nM), or TMZ (10 μM) treatment, and the resulting lysates were subjected to western blot analysis with the indicated primary antibodies. C: control, O: 6OTD, T: TMZ. Full-length blots are presented in Supplementary Figure S1.
